DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Design of the Study and Selection of Subjects
2.2. Procedures
2.2.1. Anthropometry
2.2.2. Perivesicular Inflammation Findings
2.2.3. DPP-4 Serum Levels
2.3. Statistical Analysis
3. Results
3.1. Basic Information of the Participants
3.2. DPP-4 Serum Levels in Patients with Perivesicular Inflammation Data
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- De Chiara, L.; Rodríguez-Piñeiro, A.M.; Cordero, O.J.; Rodríguez-Berrocal, F.J.; Ayude, D.; Rivas-Hervada, F.J.; de la Cadena, M.P. Soluble CD26 Levels and Its Association to Epidemiologic Parameters in a Sample Population. Dis. Markers 2009, 27, 311–316. [Google Scholar] [CrossRef]
- Ohnuma, K.; Hatano, R.; Komiya, E.; Otsuko, H.; Itoh, T.; Iwao, N.; Kaneko, Y.; Dang, N.H.; Morimoto, C. A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target. Front. Biosci. 2018, 23, 1754–1779. [Google Scholar] [CrossRef]
- Fasshauer, M.; Blüher, M. Adipokines in health and disease. Trends Pharmacol. Sci. 2015, 36, 461–470. [Google Scholar] [CrossRef] [PubMed]
- Durinx, C.; Lambeir, A.-M.; Bosmans, E.; Falmagne, J.-B.; Berghmans, R.; Haemers, A.; Scharpé, S.; De Meester, I. Molecular characterization of dipeptidyl peptidase activity in serum: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 2000, 267, 5608–5613. [Google Scholar] [CrossRef] [PubMed]
- Yazbeck, R.; Jaenisch, S.E.; Abbott, C.A. Potential disease biomarkers: Dipeptidyl peptidase 4 and fibroblast activation protein. Protoplasma 2018, 255, 375–386. [Google Scholar] [CrossRef] [PubMed]
- Röhrborn, D. DPP4 in diabetes. Front. Immunol. 2015, 6, 386. [Google Scholar] [CrossRef] [PubMed]
- Larrinaga, G.; Blanco, L.; Sanz, B.; Perez, I.; Gil, J.; Unda, M.; Andrés, L.; Casis, L.; López, J.I. The impact of peptidase activity on clear cell renal cell carcinoma survival. Am. J. Physiol. Renal Physiol. 2012, 303, F1584–F1591. [Google Scholar] [CrossRef] [PubMed]
- Pandey, K.C.; De, S.; Mishra, P.K. Role of Proteases in Chronic Obstructive Pulmonary Disease. Front. Pharmacol. 2017, 8, 512. [Google Scholar] [CrossRef] [PubMed]
- Somborac-Bačura, A.; Buljević, S.; Rumora, L.; Čulić, O.; Detel, D.; Pancirov, D.; Popović-Grle, S.; Varljen, J.; Čepelak, I.; Žanić-Grubišić, T. Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD. Clin. Biochem. 2012, 45, 1245–1250. [Google Scholar] [CrossRef] [PubMed]
- Chang, X.-Y.; Yang, Y.; Jia, X.-Q.; Wang, Y.; Peng, L.-N.; Ai, X.-H.; Jiang, C.-Y.; Guo, J.-H.; Wu, T.-T. Expression and Clinical Significance of Serum Dipeptidyl Peptidase IV Chronic Obstructive Pulmonary Disease. Am. J. Med. Sci. 2016, 351, 244–252. [Google Scholar] [CrossRef] [PubMed]
- Busso, N.; Wagtmann, N.; Herling, C.; Chobaz-Péclat, V.; Bischof-Delaloye, A.; So, A.; Grouzmann, E. Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis. Am. J. Pathol. 2005, 166, 433–442. [Google Scholar] [CrossRef]
- Sromova, L.; Busek, P.; Sedova, L.; Sedo, A. Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity. BMC Musculoskelet. Disord. 2015, 16, 244. [Google Scholar] [CrossRef] [PubMed]
- Hildebrandt, M.; Rose, M.; Rüter, J. Dipeptidyl Peptidase IV (DP IV, CD26) in Patients with Inflammatory Bowel Disease. Scand. J. Gastroenterol. 2001, 36, 1067–1072. [Google Scholar] [CrossRef] [PubMed]
- Moran, G.W.; O’Neill, C.; Padfield, P.; McLaughlin, J.T. Dipeptidyl peptidase-4 expression is reduced in Crohn’s disease. Regulat. Pept. 2012, 177, 40–45. [Google Scholar] [CrossRef] [PubMed]
- Helmberger, H.; Kammer, B. Entzündliche Erkrankungen der Gallenblase und der Gallenwege: Teil I: Bildgebende Verfahren—Cholelithiasis—Entzündungen der Gallenblase. Radiologe 2005, 45, 479–492. [Google Scholar] [CrossRef] [PubMed]
- Mathew, G.; Bhimji, S.S. Gallbladder, Cholecystitis, Clostridial (Gangrenous, Emphysematous). In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2018. [Google Scholar]
- Gordon, C.; Chumlea, W. Roche A Stature, Recumbent Length, and Weight. In Anthropometric Standardization Reference Manual; Human Kinetics Books: Champaign, IL, USA, 1988; pp. 3–8. [Google Scholar]
- Callaway, C.W.; Chumlea, W.; Bouchard, C. Circumferences. In Anthropometric Standardization Reference Manual; Human Kinetics Books: Champaign, IL, USA, 1988; pp. 44–47. [Google Scholar]
- Knab, L.M.; Boller, A.-M.; Mahvi, D.M. Cholecystitis. Surg. Clin. N. Am. 2014, 94, 455–470. [Google Scholar] [CrossRef] [PubMed]
- Nistala, R.; Savin, V. Diabetes, hypertension, and chronic kidney disease progression: Role of DPP4. Am. J. Physiol. Renal Physiol. 2017, 312, F661–F670. [Google Scholar] [CrossRef] [PubMed]
- Blackwood, B.P.; Grabowski, J. Chronic cholecystitis in the pediatric population: An underappreciated disease process. Gastroenterol. Hepatol. Bed Bench. 2017, 10, 125–130. [Google Scholar]
Variable | n = 88 |
---|---|
* Sex (Female) | 90.90 |
* Age (Years) | 39.4 ± 12.2 |
* Body Mass Index (kg/m2) | 27.8 ± 6.4 |
1 OW/OB (%) | 65.90 |
* Waist circumference (cm) | 94.7 ± 15.1 |
** Percentage of body fat mass | 34.7 ± 11.7 |
Finding of perivesicular inflammation (%) | 27.3 |
* DPP-4 (pg/mL) | 3703.6 ± 1650.9 |
Variable | Group without Perivesicular Inflammation n = 64 | Group with Perivesicular Inflammation n = 24 | p-Value |
---|---|---|---|
° Sex (Female) | 89.06 | 95.83 | 0.325 |
* Age (Years) | 39.0 ± 11.7 | 40.6 ± 13.8 | 0.627 |
* Body Mass Index (kg/m2) | 28.2 ± 5.3 | 26.7 ± 8.7 | 0.447 |
° OW/OB (%) | 70.31 | 54.16 | 0.154 |
* Waist circumference (cm) | 94.6 ± 14.1 | 94.8 ± 17.8 | 0.954 |
** Percentage of body fat mass | 34.7 ± 10.1 | 31.5 ± 13.9 | 0.697 |
* DPP-4 (pg/mL) | 3947.6 ± 1659.5 | 3053.2 ± 1469.6 | 0.018 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Valencia-Sánchez, L.; Almendra-Pegueros, R.; Diaz R-Valdez, L.J.; Esmer-Sánchez, D.; Medina, Ú.; Gordillo-Moscoso, A. DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy. Medicina 2019, 55, 148. https://doi.org/10.3390/medicina55050148
Valencia-Sánchez L, Almendra-Pegueros R, Diaz R-Valdez LJ, Esmer-Sánchez D, Medina Ú, Gordillo-Moscoso A. DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy. Medicina. 2019; 55(5):148. https://doi.org/10.3390/medicina55050148
Chicago/Turabian StyleValencia-Sánchez, Liliana, Rafael Almendra-Pegueros, Luis Jose Diaz R-Valdez, David Esmer-Sánchez, Úrsula Medina, and Antonio Gordillo-Moscoso. 2019. "DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy" Medicina 55, no. 5: 148. https://doi.org/10.3390/medicina55050148